About 26S proteasome regulatory subunit 4
26S proteasome regulatory subunit 4 (PSMC1) is a protein
from Homo sapiens identified by UniProt accession
P62191, 440 residues long.
MolForge cross-references it against 0 known binders and
48 disease associations.
Target properties
| Protein name | 26S proteasome regulatory subunit 4 |
| UniProt accession | P62191 |
| Gene | PSMC1 |
| Organism | Homo sapiens |
| Length | 440 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (48)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.47
- HIV infection · score 0.46
- neurodevelopmental disorder with poor growth, spastic tetraplegia, and hearing loss · score 0.45
- lung adenocarcinoma · score 0.30
- glioblastoma multiforme · score 0.30
- endometrial cancer · score 0.29
- clear cell renal carcinoma · score 0.27
- gastric adenocarcinoma · score 0.27
- hepatocellular carcinoma · score 0.19
- prostate carcinoma · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P62191-F1 | alphafold | PREDICTED | 77.83 | — |
Amino-acid sequence (440 residues)
MGQSQSGGHG PGGGKKDDKD KKKKYEPPVP TRVGKKKKKT KGPDAASKLP LVTPHTQCRL KLLKLERIKD YLLMEEEFIR NQEQMKPLEE KQEEERSKVD DLRGTPMSVG TLEEIIDDNH AIVSTSVGSE HYVSILSFVD KDLLEPGCSV LLNHKVHAVI GVLMDDTDPL VTVMKVEKAP QETYADIGGL DNQIQEIKES VELPLTHPEY YEEMGIKPPK GVILYGPPGT GKTLLAKAVA NQTSATFLRV VGSELIQKYL GDGPKLVREL FRVAEEHAPS IVFIDEIDAI GTKRYDSNSG GEREIQRTML ELLNQLDGFD SRGDVKVIMA TNRIETLDPA LIRPGRIDRK IEFPLPDEKT KKRIFQIHTS RMTLADDVTL DDLIMAKDDL SGADIKAICT EAGLMALRER RMKVTNEDFK KSKENVLYKK QEGTPEGLYL
Explore 26S proteasome regulatory subunit 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets